A Study of Orally Administered IPG7236 in Healthy Adult Participants

NCT05288543 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

63

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision

Conditions

Atopic Dermatitis

Interventions

DRUG: IPG7236- Single ascending dose
DRUG: IPG7236- Multiple ascending dose
OTHER: Placebo (Part A)

Sponsor

Nanjing Immunophage Biotech Co., Ltd

Collaborators

[object Object]